ENDRA Life Sciences (NASDAQ:NDRA) Downgraded by Zacks Investment Research to Sell

ENDRA Life Sciences (NASDAQ:NDRA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States. “

Several other analysts have also recently commented on NDRA. ValuEngine upgraded ENDRA Life Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of ENDRA Life Sciences in a research report on Monday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. ENDRA Life Sciences has a consensus rating of “Buy” and a consensus target price of $6.00.

NDRA traded down $0.11 on Tuesday, reaching $0.65. The company’s stock had a trading volume of 203,600 shares, compared to its average volume of 171,141. ENDRA Life Sciences has a 1 year low of $0.63 and a 1 year high of $4.50. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.61 and a quick ratio of 1.54. The stock has a market cap of $7.67 million, a price-to-earnings ratio of -0.31 and a beta of 1.24. The business’s 50 day moving average is $1.10 and its 200 day moving average is $1.37.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its earnings results on Wednesday, November 13th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.27). As a group, research analysts forecast that ENDRA Life Sciences will post -1.11 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in ENDRA Life Sciences stock. ICM Asset Management Inc. WA boosted its holdings in ENDRA Life Sciences Inc (NASDAQ:NDRA) by 3.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 696,201 shares of the company’s stock after acquiring an additional 21,875 shares during the quarter. ENDRA Life Sciences accounts for 0.9% of ICM Asset Management Inc. WA’s portfolio, making the stock its 29th largest position. ICM Asset Management Inc. WA owned about 10.50% of ENDRA Life Sciences worth $1,191,000 as of its most recent SEC filing. 16.42% of the stock is owned by institutional investors.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.

See Also: Blue-Chip Stocks

Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.